[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"notch-gene-mutation-positive-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:notch-gene-mutation-positive-tumors":20},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":16,"phases":4,"briefSummary":17,"conditions":18,"keywords":21,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":31,"locationsCount":4},"100442411","individual-patient-compassionate-use-of-nirogacestat-100442411",false,"NCT05041036","Individual Patient Compassionate Use of Nirogacestat","Inclusion Criteria:\n\n* Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.\n* Patient does not qualify to participate in an ongoing clinical trial.","ALL","EXPANDED_ACCESS","This program is being offered on a patient by patient basis and will require company, Institutional Review Board\u002FIndependent Ethics Committee, and applicable competent authority approval.",[19,20],"Desmoid Tumor","NOTCH Gene Mutation Positive Tumors",[22,23,24,25],"desmoid tumor","aggressive fibromatosis","desmoid fibromatosis","Notch-positive tumors","AVAILABLE","2026-05-04",{"date":29,"type":30},"2026-05-08","ACTUAL",{"name":32,"class":33},"SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany","INDUSTRY"]